AWMSG November medicines approvals
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Xultophy (insulin degludec and liraglutide) for use with oral antidiabetic drugs to treat adults with type 2 diabetes — it can only be used when oral treatments combined with basal insulin do not provide adequate glycaemic control; Fomicyt (fosfomycin) to treat acute osteomyelitis, complicated urinary tract infections, nosocomial lower respiratory tract infections or bacterial meningitis, or any bacteraemia believed to be associated with these infection — it should only be used when common treatments for these infections are inappropriate or have shown to be ineffective; Travatan (travoprost) for paediatric patients with ocular hypertension or paediatric glaucoma; Bramox (midodrine hydrochloride) to treat severe orthostatic hypotension due to autonomic dysfunction. The AWMSG website has the full details of restrictions.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200135
Recommended from Pharmaceutical Press